Osteonecrosis in protease inhibitor-treated patients.
Orthopedics
; 24(3): 271-2, 2001 Mar.
Article
en En
| MEDLINE
| ID: mdl-11300292
ABSTRACT
The introduction of protease inhibitors has proven a watershed in human immunodeficiency virus infection therapy and has initiated an era of highly active antiretroviral therapy. However, the numerous data on the effectiveness of these therapeutic regimens have been cited with an ever-growing number of communications concerning adverse reactions. In particular, the widescale use of protease inhibitors has underlined a series of events not evidenced in the controlled clinical studies that permitted the registration of these drugs. We are conducting a cohort multicenter study to evaluate the incidence of adverse events during treatment with protease inhibitors. To date, 4 cases of bilateral osteonecrosis of the femoral head have been reported out of 1073 person-years. While the pathogenesis of this event is unclear, it may be a long-term complication of protease inhibitor treatment.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Osteonecrosis
/
Infecciones por VIH
/
Inhibidores de la Proteasa del VIH
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Orthopedics
Año:
2001
Tipo del documento:
Article